| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| G9008 |
Coordinated care fee, physician coordinated care oversight services |
19,709 |
13,525 |
$211K |
| G9012 |
Other specified case management service not elsewhere classified |
1,731 |
902 |
$33K |
| 0510 |
|
264 |
243 |
$3K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
2,427 |
2,383 |
$3K |
| 87522 |
Neg quan hep c or qual rna |
2,169 |
2,131 |
$635.28 |
| 90750 |
|
367 |
367 |
$572.32 |
| 80061 |
Lipid panel |
11,063 |
10,879 |
$538.77 |
| 86480 |
|
642 |
629 |
$479.98 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
12,597 |
12,345 |
$438.25 |
| 90686 |
|
874 |
868 |
$420.46 |
| 80053 |
Comprehensive metabolic panel |
9,831 |
9,234 |
$391.91 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
9,076 |
8,445 |
$355.62 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
3,309 |
3,251 |
$319.38 |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
877 |
871 |
$310.30 |
| 86703 |
|
2,374 |
2,323 |
$287.16 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
714 |
699 |
$279.37 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
729 |
714 |
$278.42 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
5,486 |
5,292 |
$163.87 |
| 82274 |
|
3,592 |
3,541 |
$151.31 |
| 99442 |
|
3,324 |
3,190 |
$149.55 |
| 90662 |
|
74 |
74 |
$139.84 |
| 90715 |
|
58 |
58 |
$127.81 |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,073 |
2,014 |
$116.88 |
| 87340 |
|
1,851 |
1,828 |
$111.33 |
| 76830 |
Ultrasound, transvaginal |
136 |
127 |
$107.11 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,296 |
1,151 |
$101.10 |
| 82728 |
|
969 |
951 |
$95.60 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
17,325 |
16,824 |
$95.04 |
| 86780 |
|
703 |
693 |
$90.43 |
| 71046 |
Radiologic examination, chest; 2 views |
522 |
517 |
$89.98 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
4,566 |
4,497 |
$84.26 |
| 84153 |
|
1,090 |
1,068 |
$80.95 |
| 81001 |
|
2,504 |
2,341 |
$74.37 |
| 83550 |
|
1,168 |
1,147 |
$68.20 |
| 82043 |
|
2,889 |
2,836 |
$67.78 |
| 86141 |
|
719 |
700 |
$66.22 |
| 82607 |
|
709 |
697 |
$66.00 |
| 80076 |
|
2,715 |
2,642 |
$65.75 |
| 99441 |
|
2,272 |
2,188 |
$60.96 |
| 83540 |
|
1,231 |
1,209 |
$56.61 |
| 76770 |
|
74 |
74 |
$55.14 |
| 82540 |
|
2,889 |
2,836 |
$54.41 |
| 82746 |
|
447 |
439 |
$51.76 |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
306 |
304 |
$46.89 |
| 92250 |
|
198 |
198 |
$42.13 |
| 85610 |
|
3,938 |
2,667 |
$41.46 |
| 86706 |
|
811 |
805 |
$40.72 |
| 85027 |
|
2,849 |
2,772 |
$39.61 |
| 73030 |
|
109 |
106 |
$35.50 |
| 83970 |
|
130 |
125 |
$34.49 |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
12 |
12 |
$31.19 |
| 84439 |
|
954 |
922 |
$28.85 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
373 |
373 |
$26.63 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
14,584 |
12,634 |
$21.38 |
| 76857 |
|
60 |
55 |
$20.87 |
| 73564 |
|
190 |
188 |
$20.02 |
| 90739 |
|
94 |
94 |
$20.00 |
| 86705 |
|
428 |
422 |
$19.69 |
| 86039 |
|
69 |
68 |
$19.64 |
| 82570 |
|
142 |
134 |
$18.25 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
3,381 |
3,247 |
$18.10 |
| 73562 |
|
14 |
14 |
$17.36 |
| 84100 |
|
289 |
255 |
$16.68 |
| 85652 |
|
778 |
767 |
$14.30 |
| 84460 |
|
1,160 |
1,141 |
$13.59 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
522 |
520 |
$12.99 |
| 87338 |
|
498 |
486 |
$12.66 |
| 86708 |
|
28 |
27 |
$10.90 |
| 81003 |
|
1,017 |
977 |
$9.70 |
| 84550 |
|
236 |
235 |
$7.94 |
| 83735 |
|
80 |
68 |
$5.90 |
| 81025 |
|
46 |
42 |
$5.54 |
| 85730 |
|
227 |
224 |
$5.29 |
| 82248 |
|
70 |
68 |
$4.37 |
| 82565 |
|
582 |
559 |
$4.27 |
| 1220F |
|
3,680 |
3,579 |
$0.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
421 |
409 |
$0.00 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,467 |
2,434 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
27,987 |
24,235 |
$0.00 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
74 |
74 |
$0.00 |
| J7050 |
Infusion, normal saline solution, 250 cc |
249 |
174 |
$0.00 |
| 3074F |
|
2,702 |
2,526 |
$0.00 |
| 3044F |
|
1,378 |
1,369 |
$0.00 |
| 87088 |
|
200 |
177 |
$0.00 |
| 83001 |
|
12 |
12 |
$0.00 |
| 92227 |
|
730 |
729 |
$0.00 |
| 1111F |
|
1,315 |
1,234 |
$0.00 |
| 3080F |
|
158 |
152 |
$0.00 |
| 88142 |
|
127 |
127 |
$0.00 |
| 85018 |
|
218 |
215 |
$0.00 |
| 85008 |
|
43 |
41 |
$0.00 |
| 86901 |
|
85 |
84 |
$0.00 |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
58 |
57 |
$0.00 |
| 84132 |
|
51 |
50 |
$0.00 |
| 99606 |
|
261 |
178 |
$0.00 |
| 86850 |
|
42 |
42 |
$0.00 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
18 |
18 |
$0.00 |
| 3075F |
|
777 |
755 |
$0.00 |
| 86592 |
|
69 |
69 |
$0.00 |
| 90656 |
|
170 |
170 |
$0.00 |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
14 |
14 |
$0.00 |
| 99443 |
|
64 |
63 |
$0.00 |
| 3052F |
|
183 |
183 |
$0.00 |
| 98967 |
|
183 |
132 |
$0.00 |
| 3079F |
|
496 |
480 |
$0.00 |
| 82105 |
|
27 |
27 |
$0.00 |
| 83615 |
|
56 |
55 |
$0.00 |
| 76536 |
|
12 |
12 |
$0.00 |
| 96415 |
|
43 |
25 |
$0.00 |
| 90674 |
|
29 |
29 |
$0.00 |
| 86593 |
|
84 |
84 |
$0.00 |
| 4450F |
|
12 |
12 |
$0.00 |
| 88141 |
|
15 |
15 |
$0.00 |
| 92551 |
|
27 |
27 |
$0.00 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
15 |
13 |
$0.00 |
| 2028F |
|
102 |
98 |
$0.00 |
| 85014 |
|
218 |
215 |
$0.00 |
| 3078F |
|
3,705 |
3,388 |
$0.00 |
| 73630 |
|
128 |
126 |
$0.00 |
| 84450 |
|
819 |
810 |
$0.00 |
| 11721 |
|
407 |
406 |
$0.00 |
| 91300 |
|
231 |
225 |
$0.00 |
| 77062 |
|
161 |
161 |
$0.00 |
| 97161 |
|
136 |
135 |
$0.00 |
| 3046F |
|
299 |
298 |
$0.00 |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
277 |
277 |
$0.00 |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
45 |
45 |
$0.00 |
| 84520 |
|
39 |
38 |
$0.00 |
| 3077F |
|
707 |
656 |
$0.00 |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
124 |
78 |
$0.00 |
| 90658 |
|
96 |
96 |
$0.00 |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
92 |
92 |
$0.00 |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,074 |
661 |
$0.00 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
375 |
371 |
$0.00 |
| 3051F |
|
392 |
389 |
$0.00 |
| 77080 |
|
158 |
157 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
82 |
79 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
447 |
436 |
$0.00 |
| 98966 |
|
98 |
93 |
$0.00 |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
32 |
32 |
$0.00 |
| 87186 |
|
12 |
12 |
$0.00 |
| 86900 |
|
85 |
84 |
$0.00 |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
106 |
105 |
$0.00 |
| 98960 |
|
216 |
183 |
$0.00 |
| 76642 |
|
384 |
382 |
$0.00 |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
21 |
21 |
$0.00 |
| 85044 |
|
24 |
24 |
$0.00 |
| A4216 |
Sterile water, saline and/or dextrose, diluent/flush, 10 ml |
14 |
14 |
$0.00 |
| 77066 |
Tomosynthesis, mammo |
109 |
109 |
$0.00 |
| 77065 |
Tomosynthesis, mammo |
107 |
107 |
$0.00 |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
20 |
20 |
$0.00 |
| 99201 |
|
36 |
36 |
$0.00 |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
37 |
37 |
$0.00 |
| 82947 |
|
54 |
54 |
$0.00 |
| 11056 |
|
12 |
12 |
$0.00 |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
20 |
12 |
$0.00 |
| 90653 |
|
37 |
37 |
$0.00 |
| 86431 |
|
16 |
16 |
$0.00 |
| 92015 |
Determination of refractive state |
12 |
12 |
$0.00 |
| 73610 |
|
13 |
13 |
$0.00 |
| 2021F |
|
16 |
16 |
$0.00 |
| 90837 |
Psychotherapy, 53 minutes with patient |
20 |
15 |
$0.00 |